Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADAM12 metalloproteinase drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADAM12 ECD-Fc / Catalytic Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ADAM12 Products |
| Gene Delivery | ADAM12 Promise-ORF / Lentivirus Full-length ORF for sheddase activity assays and stable cell line construction. |
View ADAM12 Products |
| Benchmark Ab | Anti-ADAM12 (Sequence of Lead Candidate) Recombinant positive control for binding and blocking assays. |
View ADAM12 Products |
| Validator | ADAM12 siRNA Set For knockdown verification and assay specificity control. |
View ADAM12 Products |
| Related Target: ADAM9 | ADAM9 (Sheddase) Close homolog requiring cross-reactivity screening |
View ADAM9 Products |
| Related Target: ADAM17 | ADAM17/TACE Functional redundancy in HB-EGF shedding pathway |
View ADAM17 Products |
| Related Target: HB-EGF | Heparin-binding EGF-like Growth Factor Substrate validation for ADAM12 sheddase activity |
View HB-EGF Products |
| Related Target: EGFR | Downstream effector of ADAM12-mediated ligand shedding | View EGFR Products |
| Related Target: ITGB3 | Integrin β3, direct interacting partner via disintegrin domain | View ITGB3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Catalytic site selectivity vs ADAM9/ADAM17/MMPs | Purified Catalytic Domain with >95% purity; SEC-MALS verified. Theoretical MW confirmed. |
| Cross-species preclinical evaluation (Cyno/Mouse) | Human/Mouse/Cyno ADAM12 ortholog proteins; Sequence Verified; Endotoxin Controlled (<1EU/ug). |
| Membrane-bound vs shed isoform detection | Full-length Lentivirus for stable overexpression cell lines (Flow Cytometry/ELISA compatible). |
| Subfamily off-target screening | Homolog panel (ADAM9, ADAM10, ADAM17) strictly verified by mass spec (>95% purity). |
| Native glycosylation preservation | HEK293 expressed proteins ensuring human-like post-translational modifications for precise epitope recognition. |
| Lack of Controls | Clinical Benchmark Antibodies (biosimilar sequences) included. |
| False Positives | Validated siRNA included for specificity checks in cellular assays. |
Live ADAM12 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADAM12 (Meltrin-alpha) therapeutics is intensifying as the industry pivots from broad-spectrum metalloproteinase inhibitors to highly selective ADAM12 modulators. ADAM12 is highly upregulated in tumor tissues (breast, gastric, lung cancers) and fibrotic microenvironments while remaining low in normal tissues, presenting an ideal therapeutic window. First-generation selective inhibitors and antibody-based approaches (including ADCs) are entering preclinical development, with major players emphasizing combination regimens with immune checkpoint blockade and stromal remodeling agents. The next wave of R&D is targeting selective tumor microenvironment remodeling and ADC-mediated internalization to bypass systemic toxicities historically associated with pan-ADAM inhibition. Differentiation between membrane-anchored and shed isoforms is critical for precision oncology applications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule Inhibitors | Academic Consortiums, Early Biotech | Solid Tumors, Fibrosis (NASH, IPF) | Enzymatic Selectivity Assay (Need purified ADAM9/ADAM17 counter-screening proteins) |
| Monoclonal Antibodies | Preclinical Stage, Diversified IO pipeline | Breast Cancer, HCC, Solid Tumors, Fibrosis | Binding/Blocking Assay (Need high-purity ECD-Fc, human/cyno ortholog cross-reactivity) |
| ADC (Antibody-Drug Conjugate) | Leading Biotechs, Emerging Programs | Breast Cancer, Gastric Cancer, Glioblastoma, Stromal-targeted Oncology | Internalization Assay (Need full-length Lentivirus for membrane expression, pH-dependent SPR) |
Domain Architecture and Mutation Considerations
ADAM12 comprises three functional domains (Peptidase M12B, Disintegrin, EGF-like) per UniProt O43184. Key mutations include germline variant rs3740199 (missense) and somatic mutations in breast cancer samples (VAR_036143, VAR_036144). These mutations may affect protein conformation or sheddase activity. TarMart's products cover both wild-type and variant sequences to support mutation-specific assay development and preclinical selection.